IN2014MN01962A - - Google Patents

Info

Publication number
IN2014MN01962A
IN2014MN01962A IN1962MUN2014A IN2014MN01962A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A IN 1962MUN2014 A IN1962MUN2014 A IN 1962MUN2014A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A
Authority
IN
India
Prior art keywords
cabazitaxel
crystalline form
preparation
novel
novel crystalline
Prior art date
Application number
Other languages
English (en)
Inventor
Jing Li
Quanxing Yao
Original Assignee
Chongqing Taihao Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Taihao Pharmaceutical Co Ltd filed Critical Chongqing Taihao Pharmaceutical Co Ltd
Publication of IN2014MN01962A publication Critical patent/IN2014MN01962A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
IN1962MUN2014 2012-07-25 2013-07-18 IN2014MN01962A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210259595.3A CN102746258B (zh) 2012-07-25 2012-07-25 卡巴他赛的结晶形式及其制备方法
PCT/CN2013/079575 WO2014015760A1 (zh) 2012-07-25 2013-07-18 卡巴他赛的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
IN2014MN01962A true IN2014MN01962A (de) 2015-07-10

Family

ID=47026807

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1962MUN2014 IN2014MN01962A (de) 2012-07-25 2013-07-18

Country Status (8)

Country Link
US (1) US9353076B2 (de)
EP (2) EP2835369B1 (de)
JP (1) JP6329135B2 (de)
CN (1) CN102746258B (de)
AU (2) AU2013295924B2 (de)
CA (2) CA2909500C (de)
IN (1) IN2014MN01962A (de)
WO (1) WO2014015760A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764637A (zh) 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
CN104220431A (zh) * 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103819428B (zh) * 2012-11-19 2016-01-13 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
KR101429543B1 (ko) 2012-12-13 2014-08-14 주식회사 삼양바이오팜 카바지탁셀의 신규 결정형 및 그 제조방법
CN103044364B (zh) * 2013-01-07 2016-01-20 重庆泰濠制药有限公司 一种卡巴他赛无定形晶及其制备方法
WO2014128728A2 (en) * 2013-02-25 2014-08-28 Laurus Labs Private Limited Solid forms of cabazitaxel and processes for preparation thereof
CN103450119B (zh) * 2013-09-24 2015-06-17 天津炜捷制药有限公司 一种卡巴他赛晶型w及其制备方法
EP2865674A1 (de) * 2013-10-23 2015-04-29 INDENA S.p.A. Kristalline Solvatformen von Cabazitaxel
CN105461665A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n6型物质及制备方法和其组合物与用途
CN105461664A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n5型物质及制备方法和其组合物与用途
CN108883161B (zh) 2016-01-15 2023-04-04 珠海贝海生物技术有限公司 包含卡巴他赛和人血清白蛋白的组合物和制剂
US20190224332A1 (en) * 2016-09-07 2019-07-25 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
CN117205305B (zh) 2018-04-20 2024-04-26 珠海贝海生物技术有限公司 卡巴他赛的制剂和组合物
CN113429369B (zh) * 2021-07-23 2022-12-02 无锡紫杉药业有限公司 一种高效的卡巴他赛纯化方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006660A (es) 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
CN101525321B (zh) * 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
PL388144A1 (pl) * 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
CN102060815B (zh) * 2010-12-24 2012-09-26 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
CN104395759B (zh) * 2011-09-30 2017-10-13 生命技术公司 用于图像分析识别的方法和系统
CN102336726B (zh) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 一种卡巴他赛的制备方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
WO2013065070A1 (en) * 2011-11-01 2013-05-10 Fresenius Kabi Encology Ltd. Amorphous form of cabazitaxel and process for its preparation
EP2785701B1 (de) * 2011-11-28 2019-01-02 Fresenius Kabi Oncology Limited Kristalline form von carbazitaxel und herstellungsverfahren dafür
JP6025861B2 (ja) * 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
CN104220431A (zh) 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (de) * 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd Amorphes cabazitaxel
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法

Also Published As

Publication number Publication date
EP2835369A4 (de) 2015-12-02
JP2015518012A (ja) 2015-06-25
CN102746258A (zh) 2012-10-24
CN102746258B (zh) 2015-02-04
CA2909500C (en) 2018-01-09
AU2013295924B2 (en) 2016-02-18
US9353076B2 (en) 2016-05-31
AU2013295924A1 (en) 2014-10-23
WO2014015760A1 (zh) 2014-01-30
AU2016200343A1 (en) 2016-02-11
US20150141674A1 (en) 2015-05-21
CA2909500A1 (en) 2014-01-30
EP3067348A1 (de) 2016-09-14
EP2835369B1 (de) 2019-04-03
CA2870569A1 (en) 2014-01-30
JP6329135B2 (ja) 2018-05-23
AU2016200343B2 (en) 2017-03-30
EP2835369A1 (de) 2015-02-11

Similar Documents

Publication Publication Date Title
IN2014MN01962A (de)
IN2014MN01755A (de)
MY177994A (en) Therapeutically active compounds and their methods of use
NZ706739A (en) Substituted benzene compounds
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
NZ715747A (en) Syk inhibitors
MY178621A (en) Deuterated cftr potentiators
MX349159B (es) Derivados deuterados de ivacaftor.
CR20200479A (es) COMPUESTOS TERAPÉUTICAMENTE ACTIVOS Y SUS MÉTODOS DE USO (Divisional 2016-0069)
NZ708870A (en) Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
PH12016502355B1 (en) Pharmaceutical composition
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
MX2015008187A (es) Inhibidores de alk deuterados.
IN2015DN01151A (de)
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
MX376029B (es) Compuestos de isoindol.
IN2013DN02555A (de)